Skip to Main Content
Contribute Try STAT+ Today

Hello, everyone, and nice to see you again after a long holiday weekend on this side of the pond. The vacation season is now officially over, as well, and we hope you have returned feeling refreshed and invigorated. And why not? A little time off is a good thing. Besides, you can settle into your routine with a few cups of stimulation, should you need it. So while you fire up the coffee kettle, here are a few tidbits to get you going. We hope your day is smashing and, as always, we encourage you to keep in touch …

The Food and Drug Administration holds an all-day hearing today — Tuesday — about biosimilars. An assortment of speakers — drug makers, patient advocates, medical societies, payers, pharmacies, and FDA officials, notably Commissioner Scott Gottlieb — will talk about a host of topics, including drug development, market competition, interchangeability, affordability, and regulation. The session comes amid rising expectations for biosimilars and simultaneous concerns about cost and access. Here is the agenda.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.